STADA Arzneimittel AG / AGM/EGM
08.06.2010 17:53
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
At the Annual General Meeting of STADA Arzneimittel AG, which took place
today, on June 8, 2010, in Frankfurt am Main, the Executive Board, in their
remarks, confirmed the positive outlook for the STADA Group and thereby
focused on the Group's long-term growth targets for the time frame until
2014, which were published yesterday.
In the course of the Annual General Meeting, STADA's Chairman of the
Executive Board, Hartmut Retzlaff, at first reported on financial year
2009. Here, the Group was, in the Executive Board's view, able - despite a
very challenging environment, particularly due to the unfavorable
development of currency relations that are important for STADA as well as
regulatory interventions in individual national markets - to assert itself
well.
Retzlaff then detailed the operative strengths and the strategic alignment
of the Group as well as the opportunities and risks connected to this. On
behalf of the entire Executive Board, he was convinced that STADA's
business model remains sustainable and viable for the future, and that thus
in financial year 2010 there continues to be the clear opportunity for
sales and operating earnings growth as well as at least a stabilization of
operating margins.
Moreover, the focus of Retzlaff's speech was on the Group's long-term
growth targets, which were published yesterday in the context of an ad hoc
release. According to this, with sales of approx. EUR 2.15 billion, an
EBITDA of approx. EUR 430 million and net income of approx. EUR 215 million
should be reached in 2014. In this context, Retzlaff also explained the
priorities, investments and costs of the Group-wide project 'STADA - build
the future' introduced yesterday, which should contribute to achieving the
long-term targets.
The AGM endorsed all proposals of the Supervisory Board and Executive Board
apart from item 9 on the agenda. Thus, a dividend of EUR 0.55 per common
share - an increase of 3 cents or 6% compared to the previous year - was
approved. The total dividend payments of EUR 32.3 million thus represent a
dividend ratio of approx. 32% of net income. In addition, the Executive
Board and the Supervisory Board were confirmed with nearly 100% approval.
The advance resolution for the purchase and disposal of own shares found a
majority, but not the necessary qualifying majority.
The wording of today's speech of STADA's Chairman of the Executive Board
Hartmut Retzlaff as well as the exact voting results for all items on the
agenda can be found at STADA's website under www.stada.com/agm2010.
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 /
D - 61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 /
E-mail: communications@stada.de
Or visit us in the Internet at www.stada.com.
08.06.2010 17:53 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Deutschland
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf;
Freiverkehr in Berlin, Hannover, München, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: STADA AGM 2010: Focus on long-term growth targets for 2014
| Source: EQS Group AG